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A STUDY OF GPR3, GPR6, AND GPR12 AS NOVEL MOLECULAR TARGETS FOR 
CANNABIDIOL 
Alyssa S. Laun 
April 20, 2018 
The G protein-coupled receptors 3, 6, and 12 (GPR3, GPR6, and GPR12) comprise a 
family of closely related orphan receptors with no confirmed endogenous ligands. These 
receptors are constitutively active, capable of signaling through G protein and non-G 
protein mediated mechanisms. These orphan receptors have previously been reported to 
play important roles in many normal physiological functions and to be involved in a 
variety of pathological conditions. Although they are orphans, GPR3, GPR6, and GPR12 
are phylogenetically most closely related to the cannabinoid receptors. Using β-arrestin2 
recruitment and cAMP accumulation assays, we have recently found that the non-
psychoactive phytocannabinoid cannabidiol (CBD) is an inverse agonist for GPR3, 
GPR6, and GPR12. This discovery highlights these orphan receptors as potential new 
molecular targets for CBD, provides novel mechanisms of action, and suggests new 
therapeutic uses of CBD for illnesses such as Alzheimer’s disease, Parkinson’s disease, 
cancer, and infertility. Furthermore, identification of CBD as a new inverse agonist for 
GPR3, GPR6, and GPR12 provides the initial chemical scaffolds upon which potent and 
efficacious agents acting on these receptors can be developed, with the goal of 
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GPR3, GPR6, AND GPR12 INTRODUCTION 
A. Introduction 
The G protein-coupled receptors 3, 6, and 12 (GPR3, GPR6, and GPR12) comprise a 
family of closely related receptors. These three receptors share roughly 60% amino acid 
identity.1 They are also phylogenetically related to the spingosine-1-phosphate (S1P) 
receptor, lysophosphatidic acid (LPA) receptor, melanocortin receptor, and cannabinoid 
receptors.2,3 Despite being related, the similarity of GPR3, GPR6, and GPR12 to other 
receptor groups is not enough to suggest a common ligand. Since GPR3, GPR6, and 
GPR12 have no confirmed endogenous ligands, they are still classified as orphan 
receptors.4 
Recently, we have identified orphan receptors GPR3, GPR6, and GPR12 as novel 
targets for the phytocannabinoid cannabidiol (CBD).5-7 In this review, we will first survey 
the current literature detailing the molecular and functional aspects of GPR3, GPR6, and 
GPR12; this will be followed by a description of our recent discoveries involving CBD as 
a novel inverse agonist for these three orphan receptors. We will conclude by providing 
implications of our findings with regards to the mechanism of actions and the potential 
therapeutic uses of CBD. 
 
B. Cloning/ Chromosomal Localization/ Distribution 
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GPR3: GPR3 was first cloned from a mouse cDNA library in 19938, before being 
cloned from human genomic libraries by several independent groups.1,9-11  Recently, it 
was also cloned from porcine cDNA library.12 Marchese et al. 9 mapped GPR3 to 
chromosome 1p35-1p36.1. Both Song et al.1 and Iismaa et al.10 mapped this receptor to 
1p34.3-p36.1. 
GPR3 mRNA is broadly expressed in neurons in the brain regions, including the 
cortex, thalamus, hypothalamus, amygdala, hippocampus, pituitary and cerebellum.10-13 
Notably, the GPR3 protein is overexpressed in neurons in postmortem brain tissue 
sections of Alzheimer’s disease afflicted individuals.14 GPR3 mRNA is also expressed in 
the eyes, lungs, kidneys, liver, testes, and ovaries, among other tissues.10-13  
GPR6: GPR6 was first cloned from a rat cDNA library in 1994 and named 
rCNL3.15 This was followed by its cloning from human genomic DNA in 1995.1,16 Song 
et al.1 localized GPR6 to chromosomal region 6q21, and Heiber et al.16 specified that its 
chromosomal localization is 6q21-22.1. GPR6 mRNA is predominantly expressed in 
neurons in the brain, particularly the striatum (caudate, putamen, nucleus accumbens, and 
olfactory tubercle). It is also located in the frontal cortex, retrosplenial cortex, 
hippocampus, amygdala and hypothalamus to a lesser extent.15,16  
Peripheral expression of GPR6 is apparently low. Song et al.15 did not detect 
GPR6 mRNA in the heart, spleen, lung, liver, muscle, kidney, or testis in rats. However, 
Ignatov et al.17 were able to detect relatively low levels of GPR6 mRNA in testis and 
skeletal muscle in mice. 
GPR12: GPR12 was originally isolated from a rat cDNA library in 1991 and 
named R334.18 Two years later, it was isolated from a mouse cDNA library and re-named 
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GPCR01.8 The receptor was ultimately cloned from a human genomic DNA library in 
1995 and mapped to chromosomal region 13q12.1  
GPR12 mRNA was originally identified in the pituitary.18 In the brain, the 
transcript is expressed in neurons in frontal cortex, piriform cortex, thalamus, 
hypothalamus, hippocampus, amygdala, and olfactory bulb.  Peripherally, GPR12 mRNA 
is found in testis and oocytes.8,13,18,19  
C. Signaling Pathways 
Numerous groups have studied GPR3, GPR6, and GPR12 either individually or 
concurrently in regard to their coupling possibilities (Table 1). In this section, we have 
divided subsections by cell signaling pathway, rather than receptors in order to reflect 
cohesiveness.   
Gs Protein: GPR3 was first described as a constitutive activator of adenylate 
cyclase by Eggerickx et al in 1995.11 They found that GPR3 activates adenylate cyclase 
as measured by cAMP accumulation; the level of activation was comparable to other 
ligand activated, Gs-coupled receptors.  They further determined that this result was not 
due to a mutation of the receptor, and was independent of species or cell type.11 The 
group hypothesized that this constitutive activity could be due to stimulation by a 
ubiquitous ligand that may be free, membrane-bound, or membrane-derived. 
Alternatively, they propose that this could also be due to basal Gs coupling. Various 
groups have since supported this initial finding of GPR3 constitutive activation, and have 
gone on to show similar Gs activity in GPR6 and GPR12.
20-22
 
Notably in 2002, Uhlenbrock, Gassenhuber, and Kostenis20 showed that GPR3, 
GPR6, and GPR12 constitutive activity occurred in the presence of medium prepared 
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with serum. When the cells were serum starved, the constitutive activity was reduced, 
potentially suggesting the involvement of an endogenous ligand. 
Bresnick et al.21 sought to identify the signal transduction pathways used by 
various orphan GPCRs, including GPR3 and GPR12.  They used cAMP response element 
(CRE)-β-lactamase as a cAMP reporter to study orphan receptors transfected into 
HEK293 cells. The results showed that both GPR3 and GPR12 activated a Gs pathway 
since an increase of β-lactamase activity was observed after transfection with the 
respective receptor. GPR6 was not tested by this lab.  
Martin, Steurer, and Aronstam22 studied GPR3, GPR6, and GPR12 concurrently 
in 2015 and provided further evidence of constitutive activity at these receptors. Using 
Chinese hamster ovary (CHO) cells co-transfected with a CRE luciferase reporter and 
one of the three orphan receptor genes, they observed that cAMP signaling was 
constitutively stimulated. For each receptor, the constitutive stimulation observed was 
reported as greater than 200% stimulation above the baseline, which was their defined 
cutoff for constitutive activity.  
 Gi/o Protein: Some of the aforementioned groups studying the coupling to the Gs 
protein also studied Gi in parallel. Using HEK293 cells transfected with either GPR3, 
GPR6, or GPR12, Uhlenbrock, Gassenhuber, and Kostenis20 concluded that all three 
receptors were constitutively activating Gi as well. They demonstrated that adenylate 
cyclase stimulation was enhanced following treatment with pertussis toxin. Furthermore, 
overexpression of Gi reduced cAMP levels stimulated by GPR3, GPR6, and GPR12. 
Since the signaling was enhanced upon Gi inhibition by pertussis and inhibited upon Gi 
overexpression, the data suggests that the three receptors couple to Gi. 
20   
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Martin, Steurer, and Aronstam22 took a different approach to measuring Gi 
activity. Cells were co-transfected with the GPR3/6/12 and the CRE-luciferase reporter. 
Forskolin stimulation maximally stimulates cAMP production such that Gs-mediated 
production is non-significant and any constitutive coupling to Gi becomes apparent by 
inhibition of cAMP signaling. Constitutive inhibition of adenylate cyclase activity was 
defined as a 40% decrease below forskolin baseline. It is worth noting that while they 
showed GPR6 and GPR12 expression led to a decrease of CRE-luciferase reporter 
expression, they observed that GPR3 did not constitutively inhibit forskolin stimulated 
cAMP. These findings somewhat contradict the previously mentioned group20 that found 
GPR3 constitutively activated Gi.  
Ignatov et al.17 also conducted studies using pertussis toxin to inhibit Gi, but 
focused specifically in GPR6. They observed a suppression of ligand-induced Ca2+ 
mobilization in CHO cells overexpressing GPR6 following treatment of pertussis toxin, 
which suggests the role of Gi/o in GPR6-mediated Ca
2+ mobilization. In addition, Ignatov 
et al.19 suggested that GPR12 couples to Gi/o, because ligand-induced GIRK currents were 
blocked by pertussis toxin in Xenopus oocytes. 
Non-G Proteins: Tanaka et al.23 demonstrated that GPR3 acts through 
extracellular signal-regulated kinase 1/2 (ERK1/2) and protein kinase B (Akt) signaling 
to mediate anti-apoptotic effects. By downregulating GPR3 in cerebellar granule neurons, 
levels of ERK and Akt phosphorylation were reduced. This group also discovered that by 
adding a protein kinase A (PKA), ERK1/2, or phosphatidylinositol-3-kinase (PI3) 
inhibitor, the anti-apoptotic effect of GPR3 could be blocked. 
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In contrast, Ignatov et al.17 showed that GPR6 inhibits apoptotic cell death 
through a mechanism that relies on activation of sphingosine kinase in addition to 
ERK1/2 phosphorylation. In PC12 cells, GPR12 activated the ERK1/2 signaling pathway 
and caused a consequential increase in expression of Bcl-2, Bcl-xl, and SYP 24.  
Lowther et al.25 showed that GPR3 signals at the level of plasma membrane, and 
undergoes desensitization and internalization through mechanisms involving GPCR 
regulated kinase 2 and β-arrestin2.  
A group studying Alzheimer’s disease determined that GPR3 expression 
modulates amyloid β (Aβ) production through β-arrestin2.26 Neither GPR6 nor GPR12 
were included in this study. Overexpression of β-arrestin2 increased Aβ production, 
whereas silencing decreased Aβ production. GPR3 is critical for this process, as 
evidenced by the fact that elevation of Aβ by overexpression of β-arrestin2 only occured 
when GPR3 was also expressed.26  
Nelson and Sheng27 studied the GPR3-β-arrestin2 interaction by mutating the 
receptor. Through truncation of the C-terminal tail – the location at which β-arrestin2 
interacts with GPR3 – Aβ production and colocalization of GPR3 and amyloid precursor 
protein (APP) were decreased. It is clear from these results that β-arrestin2 is the key for 
the interaction between GPR3 and APP, which led to enhanced Aβ production 27. 
Yin et al.28 used the β-arrestin2 PathHunter assay system to measure β-arrestin2 
recruitment in HEK293 cells transiently transfected with GPR3, GPR6 and GPR12. 
However, they found no ligand-induced β-arrestin2 recruitment through these receptors 




Table 1  
Signaling Pathways of GPR3, GPR6, and GPR12 
Signaling 
Pathway 




↑ AC activation 11,20 
↑ cAMP reporter21,22 
Constitutively active20,22 
↑ AC activation20 









PTX treatment ↑AC 
activation20 
Gαi overexpression ↓ 
cAMP20 
No effect on cAMP reporter 
after forskolin stimulation22 
Constitutively active20  
PTX treatment ↑AC 
activation20 
Gαi overexpression ↓ 
cAMP20 
PTX treatment ↓ ligand 
induced Ca2+ 
mobilization17  














Non- G protein 
ERK1/2 
pathway 
Signals via ERK1/2 and 
Akt29 





β-arrestin2 No ligand induced β-
arrestin2 recruitment28 
Internalization and 
desensitization using GRK2 
and β-arrestin225 
Modulation of Aβ 
production via β-
arrestin226,27  








AC= adenylate cyclase; PTX= pertussis toxin; cAMP= cyclic adenosine monophosphate; ERK1/2 
= extracellular signal-regulated kinase ½; Akt= protein kinase B; GRK2= GPCR regulated kinase 







D. Potential Ligands 
GPR3: Sphingosine 1-phosphate (S1P) and dihydrosphingosine 1-phosphate 
(DHS1P) were first demonstrated to be agonists of GPR3 by the lab of Uhlenbrock, 
Gassenhuber, and Kostenis20, as activation by these ligands increased cAMP 
concentration in GPR3-transfected cells. However, this claim has been challenged by 
several groups, who could not reproduce the results using these lysophospholipid 
ligands.14,28,30 
Diphenyleneiodonium chloride (DPI) is another proposed agonist for GPR331. In 
HEK293 cells stably expressing GPR3, DPI stimulated numerous signaling pathways 
including Ca2+ mobilization, cAMP accumulation, β-arrestin2 recruitment, and receptor 
internalization. In comparison, the putative agonist S1P failed to induce either β-arrestin2 
recruitment or cAMP accumulation in cells stably expressing GPR3.  
In addition, an inverse agonist has also been identified for GPR3.32 AF64394 and 
its analogues were shown to reduce cAMP accumulation. AF64394, though, had the most 
pronounced effect out of the set of compounds tested, with a reported pIC50 of 7.3.  
GPR6: Both Uhlenbrock, Gassenhuber, and Kostenis 20 and Ignatov et al.17 
identified S1P as a ligand for GPR6 using the calcium mobilization assays, which showed 
S1P-induced and GPR6-mediated intracellular calcium release.Conflictingly, Yin et al.28 
did not detect any S1P-agonism activity for GPR6 when using the PathHunter β-arrestin2 
assay, and thus concluded that GPR6 remains an orphan receptor. 
GPR12: With the use of calcium mobilization assay, Uhlenbrock, Gassenhuber, 
and Kostenis20 proposed that S1P is a ligand for GPR12. More importantly, Ignatov et 
al.19 then showed that sphingosylphosphorylcholine (SPC) had higher affinity than S1P 
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for GPR12. The same lab that refuted the notion that lysophospholipids are ligands for 
GPR3 and GPR6 likewise reported that GPR12 did not respond to either S1P or SPC in 
their β-arrestin2 recruitment experiments.28 
In addition to these studies on S1P and SPC, reports have also been published on 
several other potential and unique ligands for GPR12. Lin et al.33 studied a set of 15 
different compounds isolated from endophytic Streptomyces sp. and found tyrosol to be 
the only ligand that promoted a significant increase in cAMP in both the CHO and 
HEK293 cells transfected with GPR12. In a separate study, the same laboratory isolated 
4-(hydroxymethyl)-5-hydroxy-2H-pyran-2-one from the marine-derived fungus 
Aspergillus flavus, and found the compound concentration-dependently stimulates cAMP 
production in cells transfected with GPR12.34 In a similar vein, Du et al.35 isolated and 
characterized various compounds from Penicillium citrinum, a volcanic ash- derived 
fungus, five of which induced cAMP production in CHO cells transfected with GPR12 at 





GPR3, GPR6, AND GPR12 PHYSIOLOGICAL IMPORTANCE 
A. GPR3 
Neurite outgrowth/neuronal cell survival: Neurite is a general term for any 
projection off of a neuron, and include dendrites and axons. In 2007, Tanaka et al.29 
showed that overexpression of the GPR3 receptor enhanced the neurite outgrowth of 
cerebellar granule neurons (Table2). In contrast, knockdown of GPR3 resulted in a 
reduction of neurite outgrowth. Interestingly, neurite outgrowth in receptor knockout 
mice could be rescued by either GPR3 or GPR12 expression. Additionally, they showed 
that GPR3 is endogenously enhanced in developing rat cerebellar granule neurons, which 
they suspect is important for development.29  
Tanaka et al.36 also demonstrated that endogenous GPR3 expression in rat 
cerebellar neurons was anti-proliferative because its knockdown via siRNA enhanced 
proliferation, whereas exogenous GPR3 expression partially antagonized proliferation. 
Exogenous GPR3 expression also correlated with an increase in p27/kip, which promotes 
mitotic exit and is another key regulator of proliferation in the developing cerebellum. In 
contrast, GPR3 knockdown decreased p27/kip expression. They further showed using cell 
cycle kinetic studies that GPR3 arrests the cell cycle at G1.36 
This group continued their research on GPR3 in cerebellar granule neurons and 
found that GPR3 is also important for neuronal cell survival. The cerebellar granule 
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neurons of GPR3 knockout mice exhibited lower survival in vitro compared to 
wild-type 23.  Brain sections from these mice also exhibited a higher number of caspase 3 
positive neurons in the internal granular layer when compared with wild-type. In terms of 
signaling, knockdown of endogenous GPR3 inhibits ERK and Akt phosphorylation under 
normal culture conditions. Inhibition of PKA, MAPK, or PI3 kinase eliminated the 
GPR3-mediated anti-apoptotic effect. Lastly, GPR3 knockout mice exhibited a larger 
infarct compared to wild-type in a model of brain ischemia.23  
Alzheimer’s disease: Alzheimer’s disease is a neurodegenerative disease with two 
distinct hallmarks: amyloid plaque formation and neurofibrillary tangles consisting of 
hyperphosphorylated tau. The first hallmark, amyloid plaques, are produced from 
accumulations of Aβ proteins.  Cleavage of the APP by γ secretase generates Aβ. The 
major species of amyloid protein synthesized from this cleavage are Aβ40 and Aβ42, 
with Aβ42 being the more fibrogenic species of the two. GPR3 has been identified as a 
mediator of Aβ production by two independent groups.14,26,27,37 
Thathiah et al.14 demonstrated that GPR3 increases γ secretase activity in vitro by 
co-transducing hippocampal neuronal cells with a direct substrate for γ secretase that 
produces Aβ (APP-C99) and GPR3.  By immunoblotting cell membrane extracts from 
HEK293 cells transfected with GPR3, they have shown that GPR3 increases cell surface 
localization of γ secretase subunits. In an Alzheimer’s disease cell culture model, 
overexpression of GPR3 increased Aβ secretion, while ablation of GPR3 using siRNA 
decreased the amount of Aβ produced. Furthermore, they demonstrated that GPR3 is 
highly expressed in the normal human brain, specifically in areas implicated in 
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Alzheimer’s disease, and can then become overexpressed in the sporadic Alzheimer’s 
disease brain.    
Using co-immunoprecipitation methods, this same group later showed that β-
arrestin2 interacts with the Aph-1a subunit of the γ-secretase complex.26 In addition, they 
demonstrated that downregulation of β-arrestin2 by siRNA in HEK-APP695 cells, as 
well as β-arrestin2 knockout in mice, led to a reduction of accumulation of the APP C-
terminal fragments Aβ40 and Aβ42. This outcome is similar to the result produced by an 
inhibitor of γ secretase. Moreover, they demonstrated that β-arrestin2 expression was 
high in Alzheimer’s disease patients’ postmortem brain, and that overexpression of β-
arrestin2 increased Aβ generation. 
The same group, Huang et al.37 later studied the importance of GPR3 in four 
different Alzhiemer’s disease transgenic mouse models. In all four of the models used, 
GPR3 knockout reduced amyloid pathology and improved memory. They also showed 
improved memory in GPR3 knockout/AD model mice.  
In 2013, Nelson and Sheng27 demonstrated that GPR3 is capable of complexing 
with APP, an interaction that is made possible by β-arrestin2. They observed that β-
arrestin2 alone failed to increase Aβ production in vitro in HEK293 cells transfected with 
APP. Only after additional transfection with GPR3 was there an increase in Aβ 
production. β-arrestin2 is important nonetheless, as siRNA knockdown of β-arrestin2 
lowered the Aβ produced in GPR3 transfected cells. In addition, Nelson and Sheng27 
showed that GPR3 co-localizes with endogenous APP in clusters, and that β-arrestin2 
also partially co-localizes with GPR3 in mature rat hippocampal neurons. Furthermore, 
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GPR3 increases the processing of APP, and the amount of Aβ produced correlates with 
the amount of GPR3-APP binding.  
Emotional behavior: GPR3 has been shown to modulate anxiety-related 
behavioral responses. Valverde et al.30 showed that GPR3 knockout mice displayed 
higher levels of avoidance to novel and unfamiliar environments compared to wild-type 
mice. This avoidance was associated with increased reactivity to stress in behavioral 
despair paradigms and to aggression in resident-intruder models. The authors determined 
that the reduced ability of GPR3 knockout mice to cope with stress was not due to 
changes in the hypothalamic-pituitary-adrenal axis since corticosterone levels were 
normal when exposed to unfamiliar environments. They did, however, observe changes 
in monoamine neurotransmission in the hippocampus, hypothalamus, and forebrain of 
GPR3 knockout mice.  
Neuropathic pain: Ruiz-Medina, Ledent, and Valverde38 studied the involvement 
of GPR3 in neuropathic pain after a spinal cord injury in mice. GPR3 knockout mice 
demonstrated hyperalgesia compared to mice positive for the receptor. Knockout mice 
also had reduced morphine anti-nociception, highlighting the importance of GPR3 in 
relieving neuropathic pain. There were no differences, however, in mechanical allodynia; 
microglia and astrocyte activation in the ipsilateral dorsal horn was comparable in both 
phenotypes, and thus inflammatory response was unaltered by the presence or absence of 
GPR3.  
Addiction: Tourino et al.39 showed that GPR3 modulates the early phases of 
cocaine reinforcement.  GPR3 knockout mice exhibited higher responses to reward from 
cocaine, self-administered more cocaine, and had increased locomotor activity compared 
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to wild-type control mice. Taken together, the authors suggested that the enhanced 
responsiveness in the early phases of reinforcement implicate GPR3 in developing 
addiction.   
Obesity: GPR3 is purported to be important for age-related obesity.40 Mice 
lacking GPR3 exhibited normal weights for the first 5 months, before subsequently 
gaining excess weight. Heterozygous and homozygous knockout mice gained 
significantly more weight than their age-matched wild-type GPR3 littermates. 
Furthermore, GPR3 knockout mice displayed increased fat droplet accumulation, higher 
triglyceride content in the liver, and higher concentrations of leptin, all of which 
correlates with the higher adiposity. GPR3 knockout mice also had lower energy 
expenditure and decreased core body temperature, as well as a decrease in several 
markers for thermogenesis.40  
Oocyte maturation /ovarian aging and ovarian failure: Prior to ovulation, oocytes 
are arrested in prophase I of meiosis. During ovulation, upon release of luteinizing 
hormone (LH), oocytes resume meiosis and undergo maturation. High levels of cAMP 
stimulated by Gs activation of adenylyl cyclase are required to maintain meiotic arrest, 
whereas LH stimulation and reduction in cAMP levels are required for meiotic 
resumption.41 GPR3 was first identified as pivotal for oocyte meiosis in 2004, when 
Mehlmann et al.42 found that GPR3, which is localized to the oocyte, maintains the 
prophase I arrest in mice. GPR3 knockout mice oocytes were able to resume meiosis 
within antral follicles. Since its discovery, many independent groups have confirmed the 




Ledent et al.46 compared young vs. aged GPR3 knockout mice to determine if age 
affected fertility when GPR3 is absent. Young GPR3 knockout mice were fertile, though 
they had progressively smaller litter sizes. In contrast, aged mice lacking the receptor 
suffered severe infertility as embryos did not develop and fragmented oocytes presented 
after superovulation. Ledent et al.46 thus concluded that GPR3 protects and possibly 

































GPR3 overexpression enhances neurite outgrowth of 
cerebellar granule neurons 
Tanaka et al.29 
GRP3 suppresses proliferation of cerebellar granule 
precursors and mediates terminal differentiation 
Tanaka et al. 
36 
GPR3 demonstrates anti-apoptotic effects and involvement 
in neuronal cell survival 




GPR3 enhances A production in neurons via  secretase 
activity; Elevated GPR3 expression is correlated with 
Alzheimer's disease progression in human post-mortem 
brain tissue 
Thathiah et al. 
14 
Both GPR3 and -arrestin2 participate in A production 
and gamma-secretase activity in Alzheimer's disease 
Thathiah et 
al.26 
GPR3-APP complexes, in the presence of  arrestin2, 
increase A production 
Nelson and 
Sheng27 
Deletion of GPR3 reduces amyloid pathology and 
improved memory in Alzheimer's disease mouse models 




GPR3 deletion is linked to higher levels of avoidance, 





GPR3 knockout mice demonstrated hyperalgesia and 





Addiction GPR3 modulates early phases of cocaine reinforcement Tourino et 
al.39 
Obesity GPR3 knock-out mice exhibit thermogenic dysfunction and 












GPR3 knockout mice display incomplete meiotic pause and 
premature ovarian aging 
Ledent et al.46 









Neurite outgrouth/neuronal cell survival: The dependence of neurite outgrowth on 
cAMP was demonstrated by Cai et al.47 (Table3). GPR6, like GPR3 and GPR12, 
increases neurite outgrowth when overexpressed in rat cerebellar granule neurons.29 
These results strongly indicate that GPR6, as well as GPR3 and GPR12, are critical for 
neurite outgrowth due to their constitutive activity to produce cAMP.  
Alzheimer’s disease: Individuals with Alzheimer’s disease have been found to 
produce C1q, a protein that binds amyloid β plaques and aids in clearance of the plaques, 
while also promoting a damaging inflammatory response 48. Benoit et al.49 found that 
through a C1q-mediated mechanism GPR6 is upregulated in Alzheimer’s disease mouse 
models. They also showed that GPR6 is crucial for the C1q-mediated neuroprotection 
against amyloid-β-induced neurotoxicity in the mouse model. As such, GPR6 may play a 
key role for neuroprotection in individuals with Alzheimer’s disease.49  
Parkinson’s disease: GPR6 also has implications for Parkinson’s disease. GPR6 
deficient mice have increased dopamine concentrations in striatal tissue, decreased cAMP 
concentration in intact mice striatum, and improved motor activity while decreasing 
abnormal movements in the mouse dyskinesia model of Parkinson’s disease.50 This 
research highlighting GPR6 as a possible target for Parkinson’s disease treatment is 
distinctly novel from dopamine-centric therapeutics. An antagonist for GPR6 could thus 
present as a therapeutic agent for Parkinson’s disease. 
Instrumental learning: The striatum is a key brain structure for integrating 
information from the cortex to substantia nigra. Lobo et al.51 found that GPR6 is essential 
for regulation of cAMP production in striatal medium spiny neurons in vitro, owing to 
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the observation that cAMP was reduced in GPR6 knockout neurons. In addition, GPR6 
knockout mice demonstrated selective changes in instrumental conditioning. This work 
suggests that GPR6 is likely key for normal learning processes, as well as a potential 
target for treatment of neuropsychiatric disorders.  
 
Table 3  











GPR6 overexpression increases neurite outgrowth of 
cerebellar granule neurons 
Tanaka et al.29 
Alzheimer’s 
disease 
GPR6 can be upregulated via a C1q-mediated method; 
GPR6 is crucial for the C1q-mediated neuroprotection 
against amyloid-β-induced neurotoxicity 
Benoit et al.49 
Parkinson’s 
disease 
GPR6-deficient mice show increased striatal dopamine and 
reduced dyskinesia in a Parkinson’s disease model 
Oeckl et al.50 
Instrumental 
learning 
GPR6 regulates cAMP production in striatal medium spiny 
neurons, and is involved in instrumental conditioning 
Lobo et al.51  















Neurite outgrowth and neuronal development: The lab of Ignatov et al.19 showed 
that the lysophospholipid SPC is a high-affinity ligand for GPR12 (Table4). By in situ 
hybridization on embryonal and adult mice brains, they determined that GPR12 
transcripts were present in the embryonal brain with a high concentration in areas of 
neuronal differentiation. In adult mouse brains, GPR12 was identified in the limbic 
system. In vitro cell culture revealed that embryonal cerebral cortical neurons had 
increased synaptic contacts following SPC treatment, and HT22 hippocampal cells 
increased cell proliferation and clustering in response to SPC. These results led the lab to 
conclude that by interacting with GPR12, SPC is able to positively influence the 
proliferation of neuronal precursor cells and the differentiation and maturation process of 
post-mitotic neurons.  
As with GPR3 and GPR6, Tanaka et al.29 showed that GPR12 overexpression also 
increased neurite outgrowth. In fact, GPR12-mediated outgrowth was the most prominent 
of the three receptors. They further showed that GPR12 activity on neurite outgrowth 
depends on Gs protein and cAMP- dependent protein kinase. In experiments in which 
GPR3 was knocked down, GPR12 also rescued neurite outgrowth. However, similar to 
GPR6, GPR12 exhibits low expression in rat cerebellar granule neurons.29,36,52 
In 2012, Lu et al.24 demonstrated that GPR12 induces neurite outgrowth in PC12 
cells. The consequences of GPR12 overexpression on PC12 cells were studied by 
transfecting PC12 cells with recombinant human GPR12. They showed that GPR12 
overexpression instigated the differentiation of PC12 cells into neuron-like cells with 
increased size of the cell and neurite generation. The researchers propose that a possible 
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mechanism for this phenotype is the activation of ERK1/2 signaling and a substantial 
increase in the expression of multiple genes related to neurite outgrowth. 
GPR12: obesity and metabolic disorders  
Bjursell et al.53  investigated the importance of GPR12 in metabolism. They found that 
food intake was not significantly affected in GPR12 knockout mice compared to wild-
type mice.  However, the GPR12 knockout mice exhibited higher body weight and body 
fat mass, lower respiratory exchange ratio, hepatic steatosis, and dyslipidemia. The 
authors concluded that GPR12 plays a significant role in energy balance, which is 
supported by the fact that GPR12 knockout mice developed obesity and lower energy 
expenditure. 
Oocyte maturation: Hinckley et al.13 studied GPR12 expression and its role in 
oocyte meiotic arrest. GPR12 mRNA is expressed in both rat and mouse oocytes. They 
demonstrated that GPR12 expression in oocytes prevents meiotic maturation, whereas 
downregulation of GPR12 allows meiotic resumption. Stimulating oocytes with the 
putative ligands S1P and SPC led to maturation. It appears from their findings that 
GPR12 is important for maintenance of meiotic arrest in oocytes. 
Cell survival and proliferation: Lu et al.54 demonstrated that GPR12 regulates cell 
proliferation and survival in HEK293 cells. Upon overexpression of GPR12, cell 
proliferation increased and cell survival was enhanced under serum deprivation 
conditions. Furthermore, when GPR12 was overexpressed they found activation of 
extracellular signal-regulated protein kinase signaling, increased total ERK1/2, and 
increased B cell lymphoma/ leukemia-2 expression.  
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Cancer: Keratin 8 (K8) is involved in cancer cell migration and invasion by 
changing the viscoelasticity of cancer cells.55 Park et al.56 showed that overexpression of 
GPR12 induces K8 phosphorylation and reorganization, and silencing of the receptor 
reduces both of these K8 processes. These data indicate that GPR12 may be a potential 
target for prevention of metastasis by developing of compounds that are able to block 
GPR12. 
 
Table 4  












SPC interacts with GPR12 and promotes the proliferation of 




GPR12 overexpression promotes neurite outgrowth Tanaka et 
al.29 










GPR12 overexpression in oocytes leads to meiotic arrest, 






GPR12 enhances cell proliferation and survival in HEK293 
cells 
Lu et al.54  
Cancer GPR12 promotes keratin 8 phosphorylation and reorganization, 
reducing cancer cell viscoelasticity 
Park et al.56 
GPR12= G protein-coupled receptor 12; SPC= sphingosylphosphorylcholine 
  
1 This chapter has been published previously Laun, A. S. & Song, Z. H. GPR3 and GPR6, 






GPR3 AND GPR6, NOVEL MOLECULAR TARGETS FOR CANNABIDIOL 
A. Introduction 
The superfamily of G-protein-coupled receptors (GPCRs) is one of the largest and 
most studied families of proteins 15,57. Its members respond to an extensive panel of 
diverse ligands and participate in an extraordinary numbers of physiological functions 
15,57. 
The orphan G protein coupled receptors GPR3 and GPR6 were originally cloned 
in the mid1990s 1,9,15,16,57. Both GPR3 and GPR6 are constitutively active and couple to 
Gs proteins 
20,22,57,58. However, for a long time these receptors are devoid of a known 
endogenous ligand, and therefore they have been classified as orphan GPCRs.     
Both GPR3 and GPR6 are expressed in the central nervous system, and have been 
implicated in health and disease of the brain. GPR3 alters emotional behaviors 30, 
modulates early phases of cocaine reinforcement 39, involves in the development of 
neuropathic pain and regulates morphine-induced antinociception 38. GPR6 participates in 
instrumental learning, and 51, and GPR6 may serve as a therapeutic target for Parkinson’s 
disease 50, as well as schizophrenia 59.  Both GPR3 and GPR6 expression are shown to be 
involved neurite outgrowth 29. Furthermore, both GPR3 and GPR6 may play roles in 
Alzheimer’s disease. GPR3 promotes the production of amyloid-β 14, whereas GPR6 
plays a neuroprotective role in amyloid-β toxicity 49.  Regarding the possible ligands for 
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GPR3 and GPR6, Uhlenbrock and co-workers identified sphingosine-1-phosphate (S-1-
P) as an endogenous ligand for GPR3 and GPR6 by demonstrating that S-1-P can induce 
cAMP production and Ca2+ mobilization in HEK293 cells transfected with this receptor 
20,60. This result was further supported for GPR6 in a later publication, since S1P was 
shown to be a high affinity ligand that increased calcium mobilization mediated by GPR6 
17. However, the claim of S-1-P as an endogenous ligands for GPR3 and GPR6 has been 
challenged by a number of research groups because they failed to observe a specific S-1-
P-induced response in cells expressing either GPR3 14,30,61 or GPR6 61. Since the 
controversy persists, GPR3 and GPR6 are still considered orphan GPCRs.  
Despite being orphans, GPR3 and GPR6 share about 35% amino acid sequence 
identity in the transmembrane region with the CB1 and CB2 cannabinoid receptors 62,63. 
In fact, Lee 62,63 called these orphans the “cannabinoid receptor-like orphan GPCRs”. In 
this study we tested various phytocannabinoids and endocannabinoids for their potential 
effects on GPR3 and GPR6 using a β-arrestin2 recruitment assay.  
B. Materials and Methods 
Materials: The PathHunter™ eXpress kits containing Chinese hamster ovary 
(CHO)-K1 cells co-expressing EA-β-arrestin2 human and GPR3-PK/GPR6-PKwere 
purchased from DiscoverX (Fremont, CA). All cannabinoid ligands were purchased from 
Cayman Chemical (Ann Arbor, MI). 
Pathhunter™ β-arrestin2 recruitment assays: PathHunter™ eXpress kits were used 
to measure GPR3- or GPR6-mediated β-arrestin2 recruitment following manufacturer’s 
instructions. In this system, Chinese hamster ovary (CHO)-K1 cell line are stably 
expressing the GPR3/GPR6 receptors which were fused to a “ProLink (PK)” fragment of 
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β-galactosidase to form GPR3-PK/GPR6-PK. The remaining sequence of β-galactosidase 
enzyme acceptor (EA) was linked to β-arrestin2 to form EA-β-arrestin2. Recruitment of 
β-arrestin2 by receptor activation causes complementation of the two enzyme fragments. 
Levels of the active enzyme are the direct result of β-arrestin2 recruitment caused by 
receptor activation and quantified using the PathHunter detection reagent containing β-
galactosidase substrates. Cells were plated in DiscoverX cell plating reagent1 in 384-well 
plates and cultured for 24-48 hours prior to experimentation in a humidified atmosphere 
at 37°C and 5% CO2. Cannabinoid ligands were diluted in cell plating reagent1. Cells 
were then incubated with ligand at 37° C following manufacturer’s recommendations, 
followed by incubation with detection reagent in the dark for 1 hour at 23°C. 
Luminescence signal was then detected using a TECAN GENios Pro microplate reader. 
Data Analysis: Ligand-induced changes in β-arrestin2 recruitment to GPR3 and 
GPR6 were expressed as percent basal relative luminescence units, which was calculated 
by dividing luminescence readings in the presence of ligands by basal luminescence 
readings, times 100. Concentration-response curves were generated by performing non-
linear regression analysis using GraphPad Prism (GraphPad Software, La Jolla, CA). 
Data were analyzed using one-way analysis of variance (ANOVA) followed by Newman-
Keuls post-test. A p< 0.05 was considered statistically significant. Data points shown are 
presented as mean ± SEM, and were obtained from three independent experiments 





The effects of endocannabinoids on GPR3 and GPR6: To determine whether 
endocannabinoids are capable of altering β-arrestin2 recruitment to GPR3/GPR6, β-
arrestin2 recruitment assays were performed using 0.1 µM and 1 µM of 
endocannabinoids anandamide (AEA), 2-arachidonoylglycerol (2-AG), virodhamine, and 
noladin ether (NE). None of the endocannabinoids tested had any significant effects on β-
arrestin2 recruitment to either GPR3 (Fig. 1A) or GPR6 (Fig. 1B) at the two 
concentrations tested. 
 
Figure 1. Effects of endocannabinoids on b-arrestin2 recruitment to GPR3 and GPR6. 
(A) Effects of endocannabinoids on β-arrestin2 recruitment to GPR3. (B) Effects of 
endocannabinoids on β-arrestin2 recruitment to GPR6. Results are expressed as percent of basal 
relative luminescence units. Data shown represent the mean ± SEM of three experiments 




The effects of phytocannabinoids on GPR3 and GPR6: To determine whether 
phytocannabinoids are capable of changing β-arrestin2 recruitment to GPR3/GPR6, b-
arrestin2 recruitment assays were performed using 0.1 µM and 1 µM of 
phytocannabinoids cannabigerol (CBG), D9-tetrahydrocannabinol (THC), cannabidiol 
(CBD), cannabinol (CBN), and cannabichromene (CBC). CBD significantly reduced β-
arrestin2 recruitment to GPR3 at the 1 µM concentration (Fig. 2A). CBD also 
significantly reduced β-arrestin2 recruitment to GPR6 at both the 0.1 µM and 1 µM 
concentrations (Fig. 2B). In contrast, none of the other phytocannabinoids tested had any 
significant effects on β-arrestin2 recruitment to either GPR3 (Fig. 2A) or GPR6 (Fig. 2B) 






Figure 2. Effects of phytocannabinoids on β-arrestin2 recruitment to GPR3 and GPR6. 
(A) Effects of phytocannabinoids on β-arrestin2 recruitment to GPR3. (B) Effects of 
phytocannabinoids on β-arrestin2 recruitment to GPR6. Results are expressed as percent of basal 
relative luminescence units. Data shown represent the mean ± SEM of three experiments 
performed in quadruplicate. Data were analyzed by one-way analysis of variance followed by 










Concentration-dependence of the effects of cannabidiol on GPR3 and GPR6: In 
the third set of experiments, we performed a concentration dependence study of the 
effects of CBD on β-arrestin2 recruitment to GPR3/GPR6. As shown in Fig. 3, CBD 
concentration-dependently decreased β-arrestin2 recruitment to both GPR3 and GPR6. 
CBD had similar efficacy on GPR3 and GPR6, with β-arrestin2 recruitment inhibited by 
39.08 (31.83-46.32) % and 44.12 (35.80-52.53) % of basal level, respectively. However, 
CBD exhibited significantly lower potency at GPR3 than at GPR6, with EC50 (95% CI) 
values of 1.22 (0.59-2.51) µM and 0.18 (0.061-0.53) µM respectively. 
 
Figure 3. Concentration-response curves of cannabidiol in inhibiting β-arrestin2 recruitment to 
GPR3 and GPR6.  
Results are expressed as percent of basal relative luminescence units. Data points shown represent 










In the present study we have used the DiscoverX PathHunter β-arrestin2 
recruitment assay to test various encannabinoids and phytocannabinoids against the 
orphan receptors GPR3 and GPR6. We chose this assay based on the facts that it has 
several advantages comparing with other kinds of assays. The first advantage of the β-
arrestin2 recruitment assay is that it gives reliable signal regardless of G protein coupling 
(Gs, Gi or Gq). Thus the measurement is direct and does not rely on measurement of 
second messengers 64. The second advantage of the PathHunter β-arrestin2 recruitment 
assay is that there are no off target receptor signal, since the signal generated depends 
only on complementation of the receptor-PK and EA-β-arrestin2 64.  
Our first objective was to test the potential effects selected endocannabinoids on 
β-arrestin2 recruitment to both GPR3 and GPR6 receptors. Two well established 
endocannabinoids 2-AG and AEA, as well as two putative endocannabinoids 
virodhamine and NE, were used. Virodhamine is similar in structure to AEA though it 
contains arachidonic acid and ethanolamide joined by an ester linkage instead of an 
amide linkage as in AEA65. NE is similar in structure to 2-AG though it contains 
arachidonic acid and glycerol joined by an ether linkage instead of an ester linkage as in 
2-AG 66 67. At a concentration of 1 µM, none of the endocannabinoids tested significantly 
altered β-arrestin2 recruitment to either GPR3 or GPR6. These data suggest that none of 
endocannabinoids tested behaves as ligands for GPR3 or GPR6. 
Secondly, we tested the effects of five major phytocannabinoids (THC, CBD, 
CBN, CBC, and CBG), on β-arrestin2 recruitment to GPR3/GPR6. Among the 
phytocannabinoids that were tested, only CBD significantly reduced β-arrestin2 
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recruitment to both GPR3 and GPR6 at a concentration of 1 µM. Therefore, here we 
identified for the first time that GPR3 and GPR6 are novel targets for CBD. 
Thirdly, we examined the concentration-dependence of CBD as an inverse agonist 
for GPR3 and GPR6. We found that CBD inhibited β-arrestin2 recruitment to both GPR3 
and GPR6 in a concentration-dependent manner, thus confirming CBD is an inverse 
agonist at both GPR3 and GPR6. 
Cannabidiol (CBD) is one of the major components of marijuana 68,69. Unlike 
tetrahydrocannabinol (THC), the major psychoactive constituent of cannabis, CBD is a 
non-psychotropic phytocannabinoid 68,69. CBD has been proposed to act on many targets, 
including enzymes and receptors. For example, CBD has been shown to act, with low 
affinity, on a variety of GPCRs. CBD has low affinity for CB1 and CB2 70, but Pertwee 71 
showed that it was able to antagonize the effect of CB1 agonists indirectly. Laprarie et al 
72 supported this finding when they identified CBD as a negative allosteric regulator of 
CB1. In addition, CBD has been demonstrated to be an agonist at serotonin 5HT1a 
receptor 73, an antagonist at GPR55 74, and an allosteric modulator of the mu and delta 
opioid receptors 75. In this study, we identified GPR3 and GPR6 as a novel targets for 
CBD. This indicates a new mechanism of action for CBD in addition to the previously 
identified targets 
GPR3 has been identified as a modulator of amyloid-β generation in a high 
throughput functional genomics screen designed to identify potential therapeutic targets 
for Alzheimer’s disease (AD) 14. Further, overexpression of GPR3 increases amyloid β 
production through a β-arrestin2 mediated pathway 26. Thus, in the case of Alzheimer’s 
disease, inverse agonist that reduces the β-arrestin2 recruitment to GPR3 may reduce 
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amyloid-β generation. In the current study, we have demonstrated for the first time that 
CBD acts an inverse agonist to inhibit β-arrestin2 recruitment to GPR3. These data 
suggest that CBD may have the potential as a therapeutic agent for Alzheimer’s disease 
by acting as an inverse agonist on GPR3. 
GPR6 has been suggested as a therapeutic target for Parkinson’s disease. 50. Oeckl 
et al showed that GPR6 knockout decreases cAMP production, enhances motor activity 
and decreases abnormal movements in a Parkinson’s disease mouse model. They suggest 
that GPR6 may provide a target for treatment of Parkinson’s disease as an alternative for 
dopamine replacement. In this case, an inverse agonist of GPR6 may reduce dyskinesia 
and improve motor activity in individuals with Parkinson’s disease. In this study, we 
have demonstrated that CBD acts as an inverse agonist for GPR6. Our novel finding of 
CBD as an inverse agonist for GPR6 may provide an additional mechanisms of action for 
the neuroprotective effect of CBD seen in Parkinson’s disease models 76,77.  
In summary, we have revealed for the first time that non-psychoactive 
phytocannbibbinoids CBD acts as a novel inverse agonist on both GPR3 and GPR6. CBD 
has been demonstrated to have potential therapeutic effects for a number of neurological 
disorders 78. Our discovery that GPR3 and GPR6 as novel targets for CBD indicates that 
some of the potential therapeutic effects of CBD, such as for Alzheimer’s disease and 





FURTHER STUDY OF CBD 
A. Structure activity relationship study of CBD 
GPR3, GPR6, and GPR12 are considered orphan receptors because their 
endogenous agonists have yet to be confirmed. However, these orphan receptors share 
35% amino acid sequence identity in the transmembrane regions with the CB1 and CB2 
cannabinoid receptors.62  Because GPR3, GPR6, and GPR12 are phylogenetically related 
to cannabinoid receptors, we recently tested various classes of cannabinoids for their 
potential effects on these three orphan receptors.  
We first sought to confirm the constitutive activity of GPR3, GPR6, and GPR12. 
Our data showed that all three receptors were constitutively active.6,7 Subsequently, we 
tested the effects of cannabinoids on GPR3 and GPR6 mediated β-arrestin2 recruitment, 
and GPR12 mediated cAMP accumulation. 
We tested two well-established endocannabinoids, 2-arachidonoyl glycerol (2-
AG) and anandamide (AEA), as well as two putative cannabinoids, noladin ether (NE) 
and virodhamine. Of the four, none had any significant effect on β-arrestin2 recruitment 
to either GPR3 or GPR6. Similarly, in cells expressing GPR12, none of the 
endocannabinoids tested altered cAMP accumulation up to 100 µM concentrations.  
We also tested five phytocannabinoids: Δ9-tetrahydrocannabinol (Δ9-THC), 
cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), and cannabichromene 
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(CBC). The majority of phytocannabinoids tested showed no significant effect on  
β-arrestin2 recruitment to either GPR3 or GPR6; CBD, being the exception, 
concentration-dependently reduced β-arrestin2 recruitment to both GPR3 and GPR6.6 We 
also found that CBD exhibited higher potency for GPR6 than for GPR3.6 With regards to 
GPR12, most of the phytocannabinoids tested had no effect up to 100 µM, again with the 
exception of CBD, which significantly decreased cAMP accumulation concentration-
dependently with an EC50 of about 10 μM.7  Together, these results demonstrate for the 
first time that GPR3, GPR6, and GPR12 are novel molecular targets for CBD, and CBD 
is a new inverse agonist for this family of orphan receptors.6,7  
Building on this discovery, we next conducted a structure-activity relationship 
analysis of CBD as an inverse agonist of GPR3, GPR6, and GPR12. We designed the 
study around CBD analogues, with changes made to either the aliphatic side chain or the 
free hydroxyl groups. Cannabidivarin (CBDV) exchanges the pentyl for a propyl side 
chain, and O-1821 substitutes the pentyl for a methyl side chain. In contrast, cannabidiol-
2’,6’-dimethyl ether (CBDD) contains the same pentyl side chain, but substitutes the 
2’,6’- hydroxyl groups with methoxyl groups. Our data showed all three derivatives to be 
less potent than the original structure of CBD.  Thus, these data demonstrate that both the 
pentyl side chain and the free hydroxyl groups are essential for the inverse agonism of 
CBD on GPR3, GPR6, and GPR12.5,7 Despite the finding of CBD action on these 
receptors, GPR3, GPR6, and GPR12 remain orphans since by definition they do not have 
a confirmed endogenous ligand. It is possible that by binding to the receptor, CBD is 
blocking the effects of an unidentified, endogenous agonists, and is therefore a neutral 
antagonist, rather than an inverse agonist for GPR3, GPR6, or GPR12. This point is 
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unsettled, and cannot be discounted without further work. While we acknowledge this 
possibility, we believe it is unlikely the case for the following two reasons. Firstly, the 
original finding of S1P/SPC agonism on these orphan receptors have been challenged by 
a number of independent groups, who could not reproduce the reported results of 
S1P/SPC agonisim.14,28,30 Secondly, in our hands neither serum deprivation nor charcoal 
stripped serum affected either the constitutive activity of these orphan receptors, or the 
CBD-induced reduction of constitutive activity. Based on these two reasons, we believe 
that CBD, is truly an inverse agonist on GPR3, GPR6 and GPR12.  
B. Molecular scaffold for future development of potent ligands 
CBD is not a potent ligand for GPR3 (EC50~1µM) and GPR6 (EC50~100 nM) in 
β-arrestin2 recruitment assay.6 Also, it is not a potent ligand for GPR12-mediated cAMP 
accumulation (EC50~10 µM).
7  Nevertheless, CBD still provides a molecular scaffold 
upon which structural changes can be made to develop new, potentially more potent and 
efficacious ligands for GPR3, GPR6, and GPR12.  
Our collaborators, Morales, Hurst, and Reggio 3 have recently developed an in 
silico model of GPR3. In developing the model, they hope to gain insight into the 
structure and function of GPR3 and use the model as a powerful tool for development of 
high affinity/potency ligands for the receptor.  Based on our experimental data of CBD as 
an inverse agonist, as well as our CBD structure-activity relationship data (i.e. 
modifications to the aliphatic side chain and free hydroxyl groups), CBD and its 
analogues can be docked within the GPR3 model. From docking, chemical modifications 
to the CBD scaffold can be designed, novel ligands can be synthesized, and these new 
compounds can be tested experimentally, with the goal of producing highly potent 
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ligands acting on GPR3. The highly potent ligands (theoretically, inverse agonists) can 
then be used as research tools to study the functions of GPR3 and perhaps can be 
developed to therapeutic agents (e.g. for the treatment of Alzheimer’s disease and 






FUTURE STUDY OF CBD AND CONCLUDING REMARKS 
A. Potential Significance and Implications of CBD 
CBD has been identified to have a wide array of health benefits. Our finding of 
novel targets for CBD prompted further research. While reviewing the literature, some 
overlap existed between which conditions GPR3, GPR6, and GPR12 may have a role, 
and those diseases for which CBD has benefit. The link is not direct, and no evidence 
supports that CBD acts through these receptors to mediate the effect. Knockout data 
showing CBD effects are absent in cells/tissues lacking these receptors would greatly 
benefit study of the receptors, study of CBD, and study of the diseases. In this section, we 
highlight some of the conditions for which CBD has exhibited benefit, and point out 
parallels between GPR3, GPR6 and GPR12 in the hopes that this is a new and exciting 
area of future research. 
Alzheimer’s disease: Within the last 20 years, CBD has been suggested to be 
beneficial for Alzheimer’s disease therapy.79 Cheng et al.80 studied the effects of CBD on 
various cognitive parameters in a mouse model of Alzheimer’s disease. After treatment 
with CBD for 3 weeks, the mice were observed to undergo a reversal of cognitive 
deficits. This study was the first to demonstrate that CBD may be an effective treatment 
for Alzheimer’s disease. 
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With regards to its mechanism, it is well documented that CBD has anti-
inflammatory, neuroprotective, and antioxidant properties. Furthermore, CBD has been 
shown to regulate microglial activation, reduce tau hyperphosphorylation, prevent 
neurodegeneration, and promote neurogenesis.79  
As mentioned above, GPR3 overexpression increases Aβ generation through β-
arrestin2, whereas GPR3 knockout decreases Aβ pathology.14,26 Therefore an inverse 
agonist for β-arrestin2 recruitment via GPR3 may reduce Aβ generation. Our new finding 
that CBD acts as an inverse on GPR3 suggests that this receptor presents a novel 
mechanism through which CBD can produce its therapeutic effects for Alzheimer’s 
disease. While still unconfirmed, this proposed novel mechanism of action of CBD in 
Alzheimer’s disease is consistent with previous reports of CBD relieving cognitive 
deficits in Alzheimer’s disease mice.80  
Parkinson’s disease: Using animal models of Parkinson’s disease (6-
hydroxydopamine treated animals), CBD has been shown to reduce the severity of 
dopamine depletion and the inhibition of tyrosine hydroxylase activity in vivo. It was 
suggested that this neuroprotective role of CBD is either anti-inflammatory or anti-
oxidant in nature. It was also pointed out that the mechanism through which CBD acts 
may be a non-CB1/CB2 mechanism.77  
As reviewed above, GPR6 is a potential therapeutic target for Parkinson’s disease. 
In 6-hydroxydopamine-treated GPR6 knockout mice, the level of dopamine depletion 
was also reduced compared with wild-type mice, which correlated with improved motor 
activities while decreasing abnormal movements.50 It is apparent from this result that an 
inverse agonist for GPR6 may be beneficial for Parkinson’s disease treatment. Our 
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finding that GPR6 is a novel molecular target for CBD further indicates this 
phytocannabinoid for Parkinson’s disease therapy. In addition to previously identified 
mechanisms, CBD working as an inverse agonist on GPR6 may alter the dopamine levels 
in striatum and produce neuroprotective effects. Further studies are warranted to elucidate 
this novel mechanism of CBD action on Parkinson’s disease. 
Cancer: CBD has been extensively studied for its anti-cancer benefits. CBD has 
been demonstrated to inhibit the progression of glioblastoma, breast, lung, prostate, and 
colon cancer 81. Several mechanism for CBD anti-cancer activity have been identified, 
including inhibition of cancer cell viability, invasion, and metastasis 81. With relevance to 
cancer metastasis, CBD has been shown to inhibit the migration of several types of 
cancer cells, including breast cancer, cervical cancer, lung cancer, and glioblastoma.81 
GPR12 has also been suggested to play a role in cancer metastasis.56 Having 
identified CBD as a novel inverse agonist for GPR12, our data suggest that CBD may 
decrease cancer cell migration by acting on GPR12 to change the viscoelasticity of 
metastatic cancer cells. Our discovery may also provide the initial chemical scaffolds 
upon which highly potent and efficacious agents acting on GPR12 may be developed 
with the ultimate goal of preventing cancer metastasis. 
Infertility: Regulation of meiotic arrest and resumption are important for 
fertility.82 Normally, cAMP is maintained at high levels in the oocyte to arrest meiosis 
and halt maturation. However, persistent meiotic arrest limits reproductive performance, 
and women with premature ovarian aging are at risk for infertility due to unregulated 
meiotic events.  
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CBD has been identified to have a role in oocyte maturation. Reich et al.83 
demonstrated that treatment with CBD induced resumption of meiosis in rat oocytes.  
Furthermore, both GPR313,42 and GPR1213 are important for meiotic arrest of oocyte. 
Since we have recently identified that CBD is an inverse agonist on both GPR36 and 
GPR127, this suggests that the mechanism for CBD to cause the resumption of meiosis in 
oocytes might be due to its inverse agonistic action on GPR3 and/or GPR12. In addition, 
our discovery of GPR3 and GPR12 as novel targets for CBD suggests that CBD and its 
derivatives might be worth exploring as novel therapeutic agents for treating infertility by 
tightly regulating meiotic arrest and resumption.  
CBD is one of the major components of marijuana. 69,84 Unlike Δ9-THC, the 
major psychoactive constituent of cannabis, CBD is a non-
psychotropic phytocannabinoid. 69,84 CBD has been proposed to act on many targets, 
including enzymes and receptors. For example, CBD has been shown to act, with low 
affinity, on a variety of GPCRs. CBD has low affinity for CB1 and CB2, 70 but Pertwee  
showed that it was able to antagonize the effect of CB1 agonists indirectly. 71 Laprarie et 
al.72 supported this finding when they identified CBD as a negative allosteric regulator of 
CB1.   In addition, CBD has been demonstrated to be an agonist at serotonin 5HT1a73,85 
and 5HT3a86 receptors, an antagonist at GPR55,74 and an allosteric modulator of the mu 
and delta opioid receptors.75 Other than working on GPCRs, CBD has also been 
identified to work as an agonist for PPAR-γ, a TRPM8 antagonist, an α1 and α3 glycine 
receptor agonist, an agonist for TRPV1 and TRPV2 channels, and a TRPA1 antagonist.87  
The discovery that GPR 3, 6 and 12 are novel targets for CBD occurred very 
recently. In this section, we have provided potential significance and implications for this
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recent discovery. While CBD has many reported targets, the recent discovery of GPR3, 
GPR6, and GPR12 as novel targets of CBD gives new perspective into the potential 
therapeutic effects of CBD and warrants further study. 
 CBD exhibits variable potency on GPR3, GPR6, and GPR12. The potency of 
CBD for GPR12 signaling is poor; the EC50 is about 10 µM which is unrealistic for a 
highly effective drug.7 We must recognize that since this potency is so low, it is unlikely 
to be the sole receptor involved in any conditions CBD may effect. The potency is higher 
however for GPR3 (EC50 1 µM) and GPR6 (EC50 100 nM).
6  The higher potency for 
these receptors indicates that CBD may be relevant for some aspects of signaling for 
these two receptors with GPR6 being the most promising target.  
B. Overall Impact and Concluding Remarks 
Misinformation and pseudoscience regarding medicinal use of cannabis, and CBD 
particularly, is rampant. With the political climate changing, and legalization of cannabis 
use in an increasing number of states in the U.S., it is imperative that the benefits and 
consequences of cannabis use be fully understood. Identification of GPR3 and GPR6 as 
molecular targets of CBD provides more insight into how the drug acts, and may explain 
some of the unexplained effects CBD has for various conditions. The information in this 
thesis and the future studies of CBD will bridge the gap in knowledge between CBD use 
and the observed benefits.  
In this thesis, we have surveyed the current literature on GPR3, GPR6, and 
GPR12 and in doing so, detailed their most significant roles in physiological functions 
and pathological processes. Our recent discovery highlights CBD as a novel inverse 
agonist for these three orphan receptors. Consequently, this offers us a new perspective 
from which to analyze the new molecular mechanisms of action for CBD.  GPR3, GPR6 
2The majority of the content within this thesis has been submitted to Acta 
Pharmacologica Sinica for publication. 
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and GPR12, being novel molecular targets for CBD, may participate in CBD-induced 
reduction of Aβ pathology, alteration of dopamine levels, inhibition of cancer cell 
migration, and regulation of meiotic arrest and resumption. Additional studies are 
warranted to further understand how GPR3, GPR6, and GPR12 mediate the CBD-
induced functional changes, and to uncover more potent ligands for each of these orphan 
receptors that can be used as research tools and perhaps novel therapeutic agents for the 
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